GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for Development of Oxbryta® (voxelotor) Tablets
Retrieved on:
Monday, October 12, 2020
GBT received the award for Oxbryta (voxelotor) tablets at a virtual event on October 9, 2020, following NORDs annual Rare Disease and Orphan Products Breakthrough Summit.
Key Points:
- GBT received the award for Oxbryta (voxelotor) tablets at a virtual event on October 9, 2020, following NORDs annual Rare Disease and Orphan Products Breakthrough Summit.
- The NORD Rare Impact Awards celebrate the individuals, groups, and companies making extraordinary contributions to the lives of rare disease patients and caregivers.
- In addition, on September 24, 2020, Oxbryta was selected by the 2020 National Xconomy Awards as Breakthrough Drug of the Year .
- Each year, the National Xconomy Awards honor the top individuals, companies, and organizations within the United States life sciences ecosystem.